Description

Tesamorelin is a stabilized GHRH analogue associated with growth-hormone release, visceral-fat reduction and body-composition support. This lyophilized vial is offered with a stated strength of 5 mg; 10 mg.

Customers receive a clearly identified Tesamorelin product with third-party testing, lot-specific documentation and straightforward storage information. Formula, molecular weight, mechanism and finished-product details are organized below for easy comparison.

Potential Benefits and Product Highlights

Stimulates the body’s growth-hormone signaling pathway.
Approved formulations have human evidence for reducing excess visceral abdominal fat in a specific medical population.
May support body-composition and lipid-metabolism goals.
Preserves pulsatile GH-axis signaling rather than supplying full growth hormone directly.
Independent third-party testing with lot-specific quality documentation.

Product Details

Product name	Tesamorelin – 5 mg / 10 mg
Main category	Peptides
Subcategory	Growth Hormone Peptides
Product format	Lyophilized vial
Declared strength	5 mg; 10 mg
Active identity / composition	Tesamorelin
Quality documentation	Independent third-party testing and lot-specific Certificate of Analysis

Chemical Information

Compound	Amount	Molecular formula	Molecular weight	Sequence / structure
Tesamorelin acetate	5 mg / 10 mg	C₂₂₁H₃₆₆N₇₂O₆₇S · xC₂H₄O₂ (x ≈ 7)	5135.9 Da free-base equivalent; acetate form varies with x	trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂

How It Works

Tesamorelin activates the GHRH receptor in the pituitary, increasing endogenous growth-hormone release and downstream IGF-1 signaling.

Ipamorelin – 5 mg offers another way to compare upstream or downstream growth-hormone-axis signaling.

Evidence note: Human evidence applies to approved prescription tesamorelin for a specific indication. Benefits, risks and monitoring should not be generalized to every product or customer. Sources: FDA. EGRIFTA SV prescribing information, 2025; PubChem. Tesamorelin compound record.

Product Strength and Usage Information

This lyophilized vial is offered with a stated strength of 5 mg; 10 mg. Check the current label, serving or unit information and lot-specific documentation before use.

No single dosage suits every compound, goal or customer. Use should follow the product label and appropriate professional guidance, especially for potent hormones, prescription-class ingredients and investigational compounds.

Quality and Testing

Identity, purity and finished-product content are reviewed as separate quality attributes. The lot-specific Certificate of Analysis should identify the methods, results, batch number, testing provider and test date.

Chromatographic testing evaluates purity and related substances.
Mass spectrometry supports molecular identity and expected mass.
Finished-product testing evaluates the supplied concentration, unit content, fill, count, uniformity or physical presentation as applicable.
Lot-specific documentation supports confident purchasing and product traceability.

Storage and Handling

Keep the sealed vial under the temperature conditions printed on the product label.
Protect from light, moisture and repeated temperature changes.
After reconstitution, follow the stated refrigeration and use-period instructions.
Avoid repeated freeze-thaw cycles and inspect the vial before use.

Frequently Asked Questions

What is included in this product?

Tesamorelin – 5 mg / 10 mg supplied in a lyophilized vial with the declared composition and strength shown in the specifications.

What is Tesamorelin – 5 mg / 10 mg?

Tesamorelin is a stabilized GHRH analogue associated with growth-hormone release, visceral-fat reduction and body-composition support.

What potential benefits are associated with it?

Potential areas of interest include stimulates the body’s growth-hormone signaling pathway, approved formulations have human evidence for reducing excess visceral abdominal fat in a specific medical population, may support body-composition and lipid-metabolism goals.

How does it work?

Tesamorelin activates the GHRH receptor in the pituitary, increasing endogenous growth-hormone release and downstream IGF-1 signaling.

How strong is the evidence?

Human evidence applies to approved prescription tesamorelin for a specific indication. Benefits, risks and monitoring should not be generalized to every product or customer.

How is product quality documented?

Independent third-party testing and a lot-specific Certificate of Analysis provide identity, purity and finished-product information.

How should the product be stored?

Keep the product in its original container and follow the temperature, light and handling conditions shown on the label.

What should be checked when the product arrives?

Review the product name, format, strength, lot number, container integrity and matching Certificate of Analysis.

Tesamorelin (5mg, 10mg)